Porter DL - Search Results

1

Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.

Svoboda J, Andreadis C, Elstrom R, Chong EA, Downs LH, Berkowitz A, Luger SM, Porter DL, Nasta S, Tsai D, Loren AW, Siegel DL, Glatstein E, Alavi A, Stadtmauer EA, Schuster SJ. Svoboda J, et al. Among authors: porter dl. Bone Marrow Transplant. 2006 Aug;38(3):211-6. doi: 10.1038/sj.bmt.1705416. Epub 2006 Jun 12. Bone Marrow Transplant. 2006. PMID: 16770314

2

Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer.

Morgan MA, Stadtmauer EA, Luger SM, Porter DL, Mangan PA, O'Neil P, Kamelle S, Benjamin I, Mick R, King SA, Rubin SC. Morgan MA, et al. Among authors: porter dl. Gynecol Oncol. 1997 Dec;67(3):272-6. doi: 10.1006/gyno.1997.4878. Gynecol Oncol. 1997. PMID: 9441774 Free article. Clinical Trial.

3

Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy.

Moore HC, Mick R, Solin LJ, Sickles C, Mangan PA, Luger SM, Fox KR, Schuchter LM, Loh E, Porter DL, Schuster S, Buzby GP, Glatstein E, Silberstein LE, Stadtmauer EA. Moore HC, et al. Among authors: porter dl. Ann Oncol. 1999 Aug;10(8):929-36. doi: 10.1023/a:1008393204854. Ann Oncol. 1999. PMID: 10509154 Free article. Clinical Trial.

4

Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination.

Stadtmauer EA, Tsai DE, Sickles CJ, Mick R, Luger SM, Porter DL, Mangan PA, Schuchter LM, Schuster SJ, Loh EY, Magee DA, Sachs RA, Wall ME, Moore J, Buzby GP, Zaleta E, Kamoun M, Silberstein LE. Stadtmauer EA, et al. Among authors: porter dl. Med Oncol. 1999 Dec;16(4):279-88. doi: 10.1007/BF02785874. Med Oncol. 1999. PMID: 10618691 Clinical Trial.

5

Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.

Visonneau S, Cesano A, Porter DL, Luger SL, Schuchter L, Kamoun M, Torosian MH, Duffy K, Sickles C, Stadtmauer EA, Santoli D. Visonneau S, et al. Among authors: porter dl. Clin Cancer Res. 2000 May;6(5):1744-54. Clin Cancer Res. 2000. PMID: 10815893 Clinical Trial.

6

Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation.

Mathias C, Mick R, Grupp S, Duffy K, Harris F, Laport G, Stadtmauer E, Luger S, Schuster S, Wasik MA, Porter DL. Mathias C, et al. Among authors: porter dl. J Hematother Stem Cell Res. 2000 Jun;9(3):393-400. doi: 10.1089/15258160050079506. J Hematother Stem Cell Res. 2000. PMID: 10894361

7

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH. Porter DL, et al. Biol Blood Marrow Transplant. 2001;7(4):230-8. doi: 10.1053/bbmt.2001.v7.pm11349810. Biol Blood Marrow Transplant. 2001. PMID: 11349810 Free article. Clinical Trial.

8

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients.

Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, Schuster SJ, Porter DL, Montone KT, Stadtmauer EA. Tsai DE, et al. Among authors: porter dl. Transplantation. 2001 Apr 27;71(8):1076-88. doi: 10.1097/00007890-200104270-00012. Transplantation. 2001. PMID: 11374406

9

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.

Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, Tsai DE, Nasta S, Gewirtz AM, Stadtmauer EA. Cohen AD, et al. Among authors: porter dl. Bone Marrow Transplant. 2002 Jul;30(1):23-8. doi: 10.1038/sj.bmt.1703602. Bone Marrow Transplant. 2002. PMID: 12105773

10

Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy.

Buckanovich RJ, Liu G, Stricker C, Luger SM, Stadtmauer EA, Schuster SJ, Duffy K, Tsai D, Pruitt A, Porter DL. Buckanovich RJ, et al. Among authors: porter dl. Ann Hematol. 2002 Jul;81(7):410-3. doi: 10.1007/s00277-002-0481-4. Epub 2002 Jul 12. Ann Hematol. 2002. PMID: 12185517

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

241 results

Search Page

Filters